Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort

Prostate Cancer and Prostatic Diseases volume 21, pages 373–378 (2018)Cite this article

Subjects

Abstract

Background

Metabolic syndrome and obesity are linked with hyperuricemia, and it has also been proposed that oxidative stress associated with hyperuricemia may promote benign prostatic hyperplasia (BPH). However, it is currently unknown whether use of antihyperuricemic medication is associated with risk of developing BPH. We studied the association between BPH and use of antihyperuricemic allopurinol in a Finnish population-based cohort.

Methods

The study cohort consisted of 74,754 men originally identified for the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC). Information on gout and BPH medication usage (5α-reductase inhibitors, 5ARIs) during 1996–2014 was obtained from the National medication reimbursement database. Information on BPH diagnoses from in- and outpatient hospital visits and BPH-related surgery was obtained from the National Health Care Registry. Men with a record of BPH at baseline was excluded. We used Cox regression to analyze risk of starting BPH medication, having a recorded diagnosis or undergoing BPH surgery by allopurinol use with adjustment for age and simultaneous use of statins, antidiabetic or antihypertensive drugs and aspirin or other NSAIDs. Medication use was analyzed as a time-dependent variable to minimize immortal time bias.

Results

Men using allopurinol had a decreased risk for all three BPH endpoints: BPH medication (HR 0.81; 95% CI 0.75–0.88), BPH diagnosis (HR 0.78; 95% CI 0.71–0.86) and BPH-related surgery (HR 0.67; 95% CI 0.58–0.76) after multivariable adjustment. The risk association did not change by cumulative use. The risk decrease disappeared after 1–2 years lag time. Only BMI modified the risk association; the risk decrease was observed only among men with BMI above the median (27.3 kg/m2); p for interaction <0.05 for each endpoint.

Conclusions

We found that allopurinol use is associated with lowered risk of BPH medication, diagnosis and surgery. A possible explanation could be antioxidative effects of urate-lowering allopurinol.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108–19.

    Article  PubMed  CAS  Google Scholar 

  2. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157–62.

    Article  PubMed  CAS  Google Scholar 

  3. De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13:613–26.

    Article  PubMed  CAS  Google Scholar 

  4. Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. J Exp Clin Cancer Res. 2016. [cited 14 Sep 2017];35. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017015/.

  5. Vital P, Castro P, Ittmann M. Oxidative stress promotes benign prostatic hyperplasia. Prostate. 2016;76:58–67.

    Article  PubMed  CAS  Google Scholar 

  6. Sangkop F, Singh G, Rodrigues E, Gold E, Bahn A. Uric acid: a modulator of prostate cells and activin sensitivity. Mol Cell Biochem. 2016;414:187–99.

    Article  PubMed  CAS  Google Scholar 

  7. Ørsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol. 2013;10:49–54.

    Article  PubMed  CAS  Google Scholar 

  8. Chen C-J, Yen J-H, Chang S-J. Gout patients have an increased risk of developing most cancers, especially urological cancers. Scand J Rheumatol. 2014;43:385–90.

    Article  PubMed  Google Scholar 

  9. Castro GD, Costantini MH, Castro JA. Rat ventral prostate xanthine oxidase-mediated metabolism of acetaldehyde to acetyl radical. Hum Exp Toxicol. 2009;28:203–8.

    Article  PubMed  CAS  Google Scholar 

  10. Zhang Z, Blake DR, Stevens CR, Kanczler JM, Winyard PG, Symons MC, et al. A reappraisal of xanthine dehydrogenase and oxidase in hypoxic reperfusion injury: the role of NADH as an electron donor. Free Radic Res. 1998;28:151–64.

    Article  PubMed  CAS  Google Scholar 

  11. Bove M, Cicero AFG, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag. 2017;13:23–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Pea F. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. Contrib Nephrol. 2005;147:35–46.

    PubMed  CAS  Google Scholar 

  13. Parikesit D, Mochtar CA, Umbas R, Hamid ARAH. The impact of obesity towards prostate diseases. Prostate Int. 2016;4:1–6.

    Article  PubMed  Google Scholar 

  14. Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, et al. Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst. 2013;105:719–25.

    Article  PubMed  Google Scholar 

  15. Sarre S, Määttänen L, Tammela TLJ, Auvinen A, Murtola TJ. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use. Scand J Urol. 2016;50:267–73.

    Article  PubMed  CAS  Google Scholar 

  16. WHOCC - ATC/DDD Index. [cited 14 Sep 2017]. Available at https://www.whocc.no/atc_ddd_index/.

  17. Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman U-H, Tammela TLJ, et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial. Prostate. 2015;75:1394–402.

    Article  PubMed  CAS  Google Scholar 

  18. Cao Y, Giovannucci E. Obesity and Prostate Cancer. Recent Results Cancer Res. 2016;208:137–53.

    Article  PubMed  CAS  Google Scholar 

  19. Huang Y, Zhang C, Xu Z, Shen J, Zhang X, Du H, et al. Clinical Study on efficacy of allopurinol in patients with acute coronary syndrome and its functional mechanism. The article is in press. Therefore: Hellenic J Cardiol 2017 (in press)

  20. Ellulu MS. Obesity, cardiovascular disease, and role of vitamin C on inflammation: a review of facts and underlying mechanisms. Inflammopharmacology. 2017;25:313–28.

    Article  PubMed  CAS  Google Scholar 

  21. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Curr Pharm Des. 2005;11:4145–51.

    Article  PubMed  CAS  Google Scholar 

  22. Szewczyk-Golec K, Tyloch J, Czuczejko J. Antioxidant defense system in prostate adenocarcinoma and benign prostate hyperplasia of elderly patients. Neoplasma. 2015;62:119–23.

    Article  PubMed  CAS  Google Scholar 

  23. Rupérez AI, Gil A, Aguilera CM. Genetics of oxidative stress in obesity. Int J Mol Sci. 2014;15:3118–44.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland

    Ville Kukko, Teuvo L. J. Tammela & Teemu J. Murtola

  2. Department of Urology, Tampere University Hospital, Tampere, Finland

    Antti Kaipia, Teuvo L. J. Tammela & Teemu J. Murtola

  3. Finnish Cancer Registry, Helsinki, Finland

    Kirsi Talala

  4. Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    Kimmo Taari

  5. Faculty of Social Sciences, University of Tampere, Tampere, Finland

    Anssi Auvinen

Authors
  1. Ville Kukko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antti Kaipia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirsi Talala
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kimmo Taari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Teuvo L. J. Tammela
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Anssi Auvinen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teemu J. Murtola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ville Kukko.

Ethics declarations

Conflict of interest

T.L.J. Tammela: consultant fees from Astellas, Bayer, and Roche. T.J. Murtola: consultant fees from Astellasand Janssen Cilag. Lecture fees from Astellas, GSK, and Janssen Cilag. K Taari: Consultant fee from Abbvie, research funding from Medivation, travel support from Astellas, and Orion. Remaining authors declare no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kukko, V., Kaipia, A., Talala, K. et al. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis 21, 373–378 (2018). https://doi.org/10.1038/s41391-017-0031-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41391-017-0031-8

This article is cited by

Search

Advanced search

Quick links